Dario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement
DarioHealth Corp. (DRIO) announced a new collaboration with a top-six U.S. pharmaceutical company to utilize Dario Connect for enhancing patient engagement with a new psoriasis drug. The partnership marks a shift from milestone-based to recurring subscription revenue model. The collaboration includes a fixed configuration fee followed by platform and services subscription fees, enabling patient medical record aggregation and providing pharmaceutical companies access to de-identified data for monitoring outcomes and prescription trends.
DarioHealth Corp. (DRIO) ha annunciato una nuova collaborazione con una delle prime sei aziende farmaceutiche statunitensi per utilizzare Dario Connect al fine di migliorare l'engagement dei pazienti con un nuovo farmaco per la psoriasi. Questa partnership segna un cambiamento da un modello di entrate basato su obiettivi a uno basato su abbonamenti ricorrenti. La collaborazione prevede una commissione di configurazione fissa seguita da canoni di abbonamento per la piattaforma e i servizi, permettendo l'aggregazione dei registri medici dei pazienti e fornendo alle aziende farmaceutiche accesso a dati anonimizzati per il monitoraggio dei risultati e delle tendenze prescrittive.
DarioHealth Corp. (DRIO) anunció una nueva colaboración con una de las seis principales compañías farmacéuticas de EE. UU. para utilizar Dario Connect con el fin de mejorar la participación de los pacientes con un nuevo medicamento para la psoriasis. Esta colaboración marca un cambio de un modelo de ingresos basado en hitos a uno basado en suscripciones recurrentes. La asociación incluye una tarifa de configuración fija seguida de tarifas de suscripción para la plataforma y los servicios, permitiendo la agregación de registros médicos de los pacientes y proporcionando a las compañías farmacéuticas acceso a datos desidentificados para monitorear resultados y tendencias de prescripción.
DarioHealth Corp. (DRIO)는 미국 주요 제약사 중 하나와 협력하여 Dario Connect를 활용해 새로운 건선 약물에 대한 환자 참여를 개선한다고 발표했습니다. 이 파트너십은 성과 기반 수익 모델에서 반복 구독 수익 모델로의 전환을 의미합니다. 협력에는 고정 구성 요금이 포함되며, 그 후 플랫폼 및 서비스 구독 요금이 따르며, 이는 환자 의료 기록의 집합을 가능하게 하고 제약 회사들에 대해 데이터 비식별 처리에 대한 접근을 제공하여 결과 및 처방 트렌드를 모니터링할 수 있게 합니다.
DarioHealth Corp. (DRIO) a annoncé une nouvelle collaboration avec une des six principales entreprises pharmaceutiques américaines pour utiliser Dario Connect afin d'améliorer l'engagement des patients avec un nouveau médicament contre le psoriasis. Ce partenariat marque un passage d'un modèle de revenus basé sur des jalons à un modèle de revenus par abonnement récurrent. La collaboration inclut des frais de configuration fixes suivis de frais d'abonnement pour la plateforme et les services, permettant l'agrégation des dossiers médicaux des patients et fournissant aux entreprises pharmaceutiques un accès à des données anonymisées pour surveiller les résultats et les tendances de prescription.
DarioHealth Corp. (DRIO) hat eine neue Zusammenarbeit mit einem der sechs größten US-Pharmaunternehmen angekündigt, um Dario Connect zu nutzen, um die Patientenbeteiligung mit einem neuen Psoriasis-Medikament zu verbessern. Die Partnerschaft stellt einen Wechsel von einem ergebnisbasierten zu einem wiederkehrenden Abonnement-Einnahmemodell dar. Die Zusammenarbeit beinhaltet eine feste Konfigurationsgebühr, gefolgt von Abonnementgebühren für die Plattform und die Dienstleistungen, die die Aggregation von Patientenakten ermöglichen und den Pharmaunternehmen den Zugang zu anonymisierten Daten zur Überwachung von Ergebnissen und Verschreibungstrends bieten.
- New revenue stream through subscription-based model with major pharma company
- Strategic shift from milestone-based to recurring revenue model
- Partnership with top-six U.S. pharmaceutical company enhances market position
- Access to valuable de-identified patient data creates additional business opportunities
- None.
Insights
This strategic partnership marks a significant pivot in Dario's business model, transitioning from milestone-based revenue to recurring subscription fees. The collaboration with a top-six U.S. pharma company for psoriasis treatment represents a substantial opportunity in the
The deal's structure indicates potential for scalable revenue growth, as successful implementation could lead to expanded use across the pharma company's other drug programs. This business model transformation could significantly improve revenue predictability and margins, while the data analytics component adds a competitive moat. However, execution risks remain, particularly around patient adoption rates and data privacy compliance.
This partnership signals Dario's evolution from a pure digital health platform to a strategic pharma industry partner. The collaboration model addresses two critical industry pain points: patient engagement and real-world evidence collection. By facilitating direct patient engagement and providing aggregated health data, Dario positions itself as an essential intermediary in the pharmaceutical value chain.
The shift to subscription-based revenue is particularly noteworthy as it could reduce revenue volatility and improve valuation multiples, typically seen in SaaS business models. For a company with a market cap under
The new platform services subscription contract with a top six U.S. pharma client marks a pivotal shift in Dario's pharma channel, transitioning the business model from milestone-based to recurring service subscription fees by expanding engagement with payors and pharmacy benefit managers (PBMs)
In an effort to strengthen and expand connections across patient populations that are candidates for a new drug to treat psoriasis, a top pharmaceutical company chose Dario to pilot a cutting-edge initiative aimed to help onboard patients that will engage with the drug via the platform. This collaboration is designed to collect critical insights on patient outcomes and drug effectiveness, with Dario Connect's innovative community-building capabilities playing a key role in enhancing patient engagement.
Dario Connect's collaboration goes beyond just connecting patients with the new drug. As part of the contract, a participating consumer health platform will work in congruence with the pharma company to enable patients to aggregate all of their medical records in one place. This allows the pharmaceutical companies to access de-identified, aggregate data to monitor patient outcomes and gain insights into prescription trends for the drug. The financial structure of the collaboration with Dario will start with a fixed configuration fee, followed by a platform and services subscription fee structure that allows Dario Connect to continue to bring engaged patients directly to the pharma company's digital environment.
"Dario Connect's advanced approach aims to redefine how pharmaceutical companies engage with patients, offering unparalleled opportunities for data-driven insights and patient support that can shape the future of healthcare. We are excited to stand at the forefront of this industry trend, with this new and innovative use for our product, especially with one of the top ten global and top six
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected new pharma collaboration; the benefits of Dario Connect's technology for patients and pharmaceutical companies; the financial structure of the collaboration with Dario; Dario's pharma channel pipeline; and Dario anticipating seeing more recurring revenue-based collaborations going forward. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/dario-expands-pharma-collaborations-with-global-pharma-leader-to-enhance-user-engagement-302295271.html
SOURCE DarioHealth Corp.
FAQ
What is the new collaboration announced by DarioHealth (DRIO)?
How will DarioHealth (DRIO) generate revenue from the new pharma collaboration?
What features does Dario Connect provide in the new pharmaceutical partnership?
